2.14
price up icon11.46%   0.22
after-market After Hours: 2.04 -0.10 -4.67%
loading
Perspective Therapeutics Inc stock is traded at $2.14, with a volume of 841.60K. It is up +11.46% in the last 24 hours and down -15.08% over the past month. Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$1.92
Open:
$1.95
24h Volume:
841.60K
Relative Volume:
1.10
Market Cap:
$154.77M
Revenue:
$6.96M
Net Income/Loss:
$-46.51M
P/E Ratio:
-12.47
EPS:
-0.1716
Net Cash Flow:
$-37.99M
1W Performance:
+2.39%
1M Performance:
-15.08%
6M Performance:
-82.73%
1Y Performance:
-86.01%
1-Day Range:
Value
$1.93
$2.15
1-Week Range:
Value
$1.75
$2.15
52-Week Range:
Value
$1.60
$19.05

Perspective Therapeutics Inc Stock (CATX) Company Profile

Name
Name
Perspective Therapeutics Inc
Name
Phone
509-375-1202
Name
Address
350 Hills Street, Suite 106, Richland
Name
Employee
91
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
CATX's Discussions on Twitter

Compare CATX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
CATX
Perspective Therapeutics Inc
2.14 154.77M 6.96M -46.51M -37.99M -0.1716
Medical Devices icon
ABT
Abbott Laboratories
131.73 218.91B 41.95B 13.40B 6.35B 7.65
Medical Devices icon
BSX
Boston Scientific Corp
95.05 139.37B 16.75B 1.85B 2.37B 1.25
Medical Devices icon
SYK
Stryker Corp
348.12 134.90B 22.60B 2.99B 3.49B 7.76
Medical Devices icon
MDT
Medtronic Plc
83.37 106.90B 33.20B 4.26B 5.47B 3.29
Medical Devices icon
EW
Edwards Lifesciences Corp
70.60 41.45B 5.72B 4.17B 259.90M 6.97

Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-13-25 Initiated H.C. Wainwright Buy
Mar-07-25 Initiated Scotiabank Sector Outperform
Nov-25-24 Downgrade BofA Securities Buy → Neutral
Oct-24-24 Initiated UBS Buy
Oct-01-24 Initiated Wedbush Outperform
Sep-25-24 Initiated Truist Buy
Jul-25-24 Initiated BofA Securities Buy
May-09-24 Initiated Cantor Fitzgerald Overweight
View All

Perspective Therapeutics Inc Stock (CATX) Latest News

pulisher
Apr 17, 2025

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results | CATX Stock News - GuruFocus

Apr 17, 2025
pulisher
Apr 17, 2025

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results - The Manila Times

Apr 17, 2025
pulisher
Apr 17, 2025

Perspective Therapeutics, Inc. to Announce Q1 2025 Financial Results and Business Update on May 12, 2025 - Nasdaq

Apr 17, 2025
pulisher
Apr 17, 2025

Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial - Bluefield Daily Telegraph

Apr 17, 2025
pulisher
Apr 17, 2025

Perspective Therapeutics Q1 2025 Earnings: Key Business Updates Coming May 12What to Watch - Stock Titan

Apr 17, 2025
pulisher
Apr 14, 2025

Arrowstreet Capital Limited Partnership Has $117,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Apr 14, 2025
pulisher
Apr 12, 2025

KLP Kapitalforvaltning AS Invests $79,000 in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Apr 12, 2025
pulisher
Apr 12, 2025

Truist Financial Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - MarketBeat

Apr 12, 2025
pulisher
Apr 12, 2025

Perspective Therapeutics (PSTH) Advances Trial for Melanoma Trea - GuruFocus

Apr 12, 2025
pulisher
Apr 12, 2025

Perspective Therapeutics Announces First Patient Dosed with [212 - GuruFocus

Apr 12, 2025
pulisher
Apr 11, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Apr 11, 2025
pulisher
Apr 11, 2025

Perspective Therapeutics Doses First Patient in New Melanoma Trial Cohort With [212Pb]VMT01 Monotherapy - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma - The Manila Times

Apr 11, 2025
pulisher
Apr 11, 2025

Perspective Therapeutics Announces First Patient Dosed With Vmt01 Monotherapy In A Phase 1/2A Study Of MC1R-Positive Metastatic Melanoma - MarketScreener

Apr 11, 2025
pulisher
Apr 11, 2025

Breakthrough Melanoma Treatment Shows Promise for Brain Metastasis Patients in Latest Trial - Stock Titan

Apr 11, 2025
pulisher
Apr 09, 2025

Is Now The Time To Invest In Perspective Therapeutics? (NYSE:CATX) - Seeking Alpha

Apr 09, 2025
pulisher
Apr 08, 2025

Perspective Therapeutics (NYSE:CATX) Given New $10.00 Price Target at Truist Financial - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Truist cuts Perspective Therapeutics target to $10, maintains Buy By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Truist cuts Perspective Therapeutics target to $10, maintains Buy - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Paraganglioma Treatment Market Size in 7MM is expected to grow - openPR.com

Apr 07, 2025
pulisher
Apr 07, 2025

Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating - marketscreener.com

Apr 07, 2025
pulisher
Apr 04, 2025

CATX stock touches 52-week low at $1.87 amid market challenges - Investing.com Australia

Apr 04, 2025
pulisher
Apr 04, 2025

CATX stock touches 52-week low at $1.87 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025
pulisher
Apr 04, 2025

What is HC Wainwright’s Estimate for CATX Q2 Earnings? - Defense World

Apr 04, 2025
pulisher
Apr 04, 2025

Perspective Therapeutics, Inc. (NYSE:CATX) Given Consensus Rating of “Buy” by Analysts - Defense World

Apr 04, 2025
pulisher
Apr 03, 2025

Pheochromocytoma Treatment Market Size in 7MM is expected - openPR.com

Apr 03, 2025
pulisher
Apr 03, 2025

Pheochromocytomas and Paragangliomas Treatment Market Size - openPR.com

Apr 03, 2025
pulisher
Apr 02, 2025

Down -16.6% in 4 Weeks, Here's Why Perspective Therapeutics (CATX) Looks Ripe for a Turnaround - Yahoo Finance

Apr 02, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Robert Williamson buys $132,151 in stock - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective therapeutics CEO Johan Spoor buys $59,672 in stock - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Robert Williamson buys $132,151 in stock By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Lori Woods acquires $49,999 in stock By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics CFO Graham Juan acquires $74,945 in stock By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics director Lori Woods acquires $49,999 in stock - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics (NYSE:CATX) Receives "Buy" Rating from HC Wainwright - MarketBeat

Apr 01, 2025
pulisher
Apr 01, 2025

Pharma-Biotech Market Development Analysis Report 2025: Growth Opportunities Shaped by a Convergence of Scientific Innovation, Regulatory Evolution, and Market Pressures - GlobeNewswire Inc.

Apr 01, 2025
pulisher
Apr 01, 2025

Perspective Therapeutics (NYSE:CATX) Given “Buy” Rating at HC Wainwright - Defense World

Apr 01, 2025
pulisher
Mar 31, 2025

Perspective Therapeutics to Participate in Upcoming April Investor Conferences - The Manila Times

Mar 31, 2025
pulisher
Mar 31, 2025

Cancer Treatment Innovator Perspective Therapeutics Lines Up Major April Investor Events - Stock Titan

Mar 31, 2025
pulisher
Mar 31, 2025

Swiss National Bank Has $275,000 Stock Holdings in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

Research Analysts Issue Forecasts for CATX Q1 Earnings - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

CATX Q1 EPS Forecast Lowered by Brookline Capital Management - Defense World

Mar 31, 2025
pulisher
Mar 30, 2025

HighTower Advisors LLC Has $568,000 Position in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Charles Schwab Investment Management Inc. Sells 26,556 Shares of Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Royal Bank of Canada Issues Pessimistic Forecast for Perspective Therapeutics (NYSE:CATX) Stock Price - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Bank of New York Mellon Corp Grows Stake in Perspective Therapeutics, Inc. (NYSE:CATX) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Analysts Offer Insights on Healthcare Companies: Allurion Technologies (ALUR), Perspective Therapeutics (CATX) and Nkarta (NKTX) - The Globe and Mail

Mar 27, 2025
pulisher
Mar 27, 2025

RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 27, 2025
pulisher
Mar 27, 2025

Perspective Therapeutics earnings missed by $0.37, revenue fell short of estimates - Investing.com Canada

Mar 27, 2025

Perspective Therapeutics Inc Stock (CATX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
medical_devices ZBH
$97.44
price up icon 1.32%
medical_devices PHG
$24.14
price up icon 3.65%
medical_devices STE
$222.77
price up icon 1.82%
$66.33
price up icon 0.33%
$61.65
price up icon 1.93%
medical_devices EW
$70.60
price up icon 2.02%
Cap:     |  Volume (24h):